Skip to content

Treatment of Schizophrenia with Aripiprazole. A one year open-label study.

Treatment of Schizophrenia with Aripiprazole. A one year open-label study examining an ultraslow switchover regime to minimise relapse and withdrawal symptoms.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12605000394640
Enrollment
40
Registered
2005-09-14
Start date
2005-01-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of this project is to investigate changeover from a person's current antipsychotic drug to a relatively new drug for the treatment of schizophrenia. This drug, Aripiprazole, works differently than any other antipsychotic drugs that have been previously available. Therefore, this study is important because the current knowledge is limited and it will allow a better understanding of a safe and effective way to switch over.

Interventions

Switchover from current antipsychotic to Aripiprazole.

Sponsors

Associate Professor Krishna Vaddadi
Lead SponsorIndividual

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
No

Inclusion criteria

Patients who are outpatients (private or public) attending southern health facility and have a well established diagnosis of schizophrenia (DSM-IV diagnosis criteria), who report side effects on their existing medication, who have not fully responded to their current therapy, who in the clinicians opinion, would benefit from Aripiprazole, who are able to comprehend what is happening to them and able to give informed consent, who can speak a reasonable level of English, and where completing rating scales with adequate information is not a practical problem.

Exclusion criteria

Patients who want to become pregnant during the study period, with alcohol dependence, with acquired brain injury associated with schizophrenia, who are on too complex medication regimes which would be difficult to change, who have previously been treated with Aripiprazole, who are on very high doses of clozapine in (>500mg/day), on very high doses of injectable Zuclopenthixol Decanoate (>200mg/fortnight), with a past history of severe violence/suicidal risk, who are generally non-compliant with oral medication, who have poor social supports and are very unreliable with appointments, and patients who are very stable on their current antipsychotic medication, but want to change to Aripiprazole simply because it is a new drug, their friend got better or, someone told them it is a good idea.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026